Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

43 results about "AMPK" patented technology

AMPK may stand for: AMP-activated protein kinase, an enzyme kinase, an enzyme

Method for promoting skeletal muscle development and application

PendingCN120700159AMicrobiological testing/measurementMuscular disorderSkeletal muscle atrophyAMPK
The invention discloses a method for promoting skeletal muscle development and application, and belongs to the technical field of biology. The invention provides a method for promoting skeletal muscle development, an AMPK / p38MAPK pathway is regulated and controlled by activating PPARalpha, the way of activating the PPARalpha is to give a PPARalpha agonist GW7647, and the regulation and control of the AMPK / p38MAPK pathway is shown as reduction of AMPK and P38 phosphorylation levels. Experiments show that the expression of MyoD, MyoG and Pax7 in skeletal muscle can be remarkably improved by activating PPARalpha, the phosphorylation level of AMPK and P38 is inhibited, and therefore muscle fiber proliferation and myoblast proliferation are promoted. The technology can be applied to livestock breeding to improve meat yield or develop drugs for treating skeletal muscle atrophy, and has remarkable economic and clinical values.
Owner:SHANXI AGRI UNIV

Application of astragaloside in preparation of product for improving heart FTO expression level

The invention relates to the field of biological medicine, in particular to application of astragaloside in preparation of a product for improving the heart FTO expression level. Research finds that astragaloside can improve expression of FTO in myocardial tissue of a Dox-induced HF mouse and improve protein and mRNA levels of AMPK and molecules such as downstream key enzymes GLUT4, PFKFB3 and CPT1A, which indicates that astragaloside can improve Dox-induced HF by regulating an FTO / AMPK signal channel and downstream molecules thereof. The research proves that the astragaloside can improve the CHF induced by adriamycin by activating the FTO / AMPK pathway, and the application range of the astragaloside is expanded.
Owner:DONGZHIMEN HOSPITAL OF BEIJING UNIV OF CHINESE MEDICINE

Methods and compositions for enhancing AMPK in mammals

A method and composition for enhancing adenosine monophosphate-activated protein kinase (AMPK) activity and improving mitochondrial-related oxidative metabolism parameters in motor and sedentary mammals by oral intake of low doses of D-ribose, thereby promoting overall metabolic health in mammals.
Owner:BIOENERGETIC LIFE SCI LTD

Methods and materials for increasing level of phosphorylated AMPK protein

This document provides methods and materials for increasing the level of phosphorylated AMPK. For example, compounds (e.g., organic compounds) having the ability to increase the level of phosphorylated AMPK within cells, formulations containing compounds having the ability to increase the level of phosphorylated AMPK within cells, methods for making compounds having the ability to increase the level of phosphorylated AMPK within cells, methods for making formulations containing compounds having the ability to increase the level of phosphorylated AMPK within cells, methods for increasing the level of phosphorylated AMPK within cells, and methods for treating mammals (e.g., humans) having a condition responsive to an increase in the level of phosphorylated AMPK are provided.
Owner:UNIV OF PITTSBURGH OF THE COMMONWEALTH SYST OF HIGHER EDUCATION

OTUB1 small-molecule binders and OTUB1-recruiting deubiquitinase-targeting chimeras (dubtacs)

PCT designated stage expiredWO2024220874A3Organic chemistryPharmaceutical non-active ingredientsAMPKProtein stabilization
Disclosed are compounds that are irreversible small-molecule binders of OTUB1 (also known as Otubain 1), and bivalent compounds (e.g. bi-functional small molecule compounds) which recruit OTUB1 through the irreversible small-molecule binders of OTUB1 to de-ubiquitinylate and stabilize proteins such as AMPK, cGAS and CFTR. Also disclosed are methods for the treatment of AMPK, cGAS and CFTR-mediated diseases in a subject in need thereof. Also disclosed are methods for designing such compounds including irreversible small-molecule binders of OTUB1 and related bivalent compounds as de-ubiquitinase-targeting chimeras (DUBTACs) for targeted protein stabilization.
Owner:MT SINAI SCHOOL OF MEDICINE +1

Amp-activated protein kinase modulator compounds and uses thereof

Compounds having activity as modulators of AMPK are provided. The compounds have Structure (I), (II), (III), or (IV):or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein R1a, R2, R3, W, X, Y, R4, R5, R6, X1, X2, X3, n, R8, R9, R10a, R10b, X4, ring A, R11, R12, R13a, R13b, and X5 are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of AMPK are also provided.
Owner:BIOLEXIS THERAPEUTICS INC

Methods and materials for increasing level of phosphorylated AMPK protein

This document provides methods and materials for increasing the level of phosphorylated AMPK. For example, compounds (e.g., organic compounds) having the ability to increase the level of phosphorylated AMPK within cells, formulations containing compounds having the ability to increase the level of phosphorylated AMPK within cells, methods for making compounds having the ability to increase the level of phosphorylated AMPK within cells, methods for making formulations containing compounds having the ability to increase the level of phosphorylated AMPK within cells, methods for increasing the level of phosphorylated AMPK within cells, and methods for treating mammals (e.g., humans) having a condition responsive to an increase in the level of phosphorylated AMPK are provided.
Owner:UNIV OF PITTSBURGH OF THE COMMONWEALTH SYST OF HIGHER EDUCATION

Compounds activating AMPK and their use

The present invention discloses a compound for activating AMPK, which is adenine and / or a pharmaceutically acceptable salt thereof. The invention also discloses the application of the compound, which is suitable for activating AMPK (AMP-activated protein kinase), and using the compound to prevent or treat physiological conditions or diseases, thereby preventing or treating physiological conditions or diseases that can be improved by AMPK in mammals.
Owner:ENERGENESIS BIOMEDICAL CO LTD

Application of herba siegesbeckiae composition in preparation of product for improving heart FTO expression level

The invention relates to the field of biological medicine, in particular to an application of a siegestistilbene composition in preparation of a product for improving the heart FTO expression level. The molecular mechanism of the herba siegesbeckiae prescription for treating HF is explored, and it is found that the herba siegesbeckiae prescription can improve expression of FTO in myocardial tissue of an HF mouse induced by Dox and improve protein and mRNA levels of AMPK and molecules of downstream key enzymes GLUT4, PFKFB3, CPT1A and the like at the same time, which indicates that the herba siegesbeckiae prescription can improve the HF induced by the Dox by regulating and controlling FTO / AMPK signal channels and downstream molecules of the FTO / AMPK signal channels. The research proves that the herba siegesbeckiae and stilbene formula can improve the CHF induced by adriamycin by regulating the FTO / AMPK pathway, and the application range of the herba siegesbeckiae and stilbene formula is expanded.
Owner:DONGZHIMEN HOSPITAL OF BEIJING UNIV OF CHINESE MEDICINE

Serum-free and protein-free culture medium for improving NK cell amplification and killing activity and preparation method of serum-free and protein-free culture medium

The invention relates to the technical field of biological medicine, in particular to a serum-free and protein-free culture medium for improving NK cell amplification and killing activity and a preparation method thereof.The serum-free and protein-free culture medium comprises a basic culture medium, an AMPK-HIF1alpha regulating agent, an immunomodulatory factor, a mitochondrial function enhancer, an antioxidant, microelements and a pH buffering agent, the AMPK-HIF1alpha regulating agent is composed of alpha-ketoglutaric acid with the final concentration of 1.4-1.6 mmol / L and AICAR with the final concentration of 0.4-0.6 mmol / L. According to the culture medium, the alpha-ketoglutaric acid and the AICAR are precisely matched to activate an AMPK-HIF1alpha channel, nicotinamide ribose and glutathione are cooperated to optimize a metabolism-antioxidant network, and the industrial problem that amplification and functions cannot be achieved at the same time in serum-free culture of NK cells is solved.
Owner:HUAXIA GENE BIOTECHNOLOGY CO LTD

Method and composition for enhancing AMPK in mammals

This method and composition involves oral administration of a low dose of D-ribose to enhance adenosine monophosphate-activated protein kinase (AMPK) activity in both exercising and sedentary mammals, improve mitochondrial-related oxidative metabolic parameters, and thereby promote overall metabolic health in mammals.
Owner:BIOENERGY INC

Methods and compositions for the ADAR-mediated editing of adenosine monophosphate (AMP)-activated protein kinase (AMPK)

PCT designated stageWO2026178077A1DiseaseAMPK
The present disclosure relates to methods and compositions for editing an AMPK polynucleotide encoding an AMPK protein. The disclosure also relates to methods and compositions for modulating activity of an AMPK protein, for promoting activation of an AMPK protein, for repairing function of a pathogenic AMPK protein, and methods for regulating energy homeostasis and / or for treating or preventing an AMPK-associated disease or condition in a subject.
Owner:KORRO BIO INC

AMPK activator (CBDA) and sglt2 inhibitors for metabolic health

A composition for synergistic activation of AMPK comprises a first compound having the general formula I and a second compound. Also provided is a method of using the composition in the synergistic activation of AMPK.
Owner:SOCIETE DES PRODUITS NESTLE SA

Bifunctional kinase binding compounds and uses thereof

PCT designated stage expiredWO2025019599A2Organic chemistryAMPKKinase binding
Provided herein are bifunctional compounds that bind 5 '-AMP-activated protein kinase (AMPK) and / or promote targeted phosphorylation of a substrate. The induced phosphorylation of the target substrate can alter the substrate's structure and function, thus providing compounds which enable phosphorylation of target substrates, including those that may not otherwise be substrates for AMPK, and providing new modes for inducing strategic phosphorylation. Also provided are pharmaceutical compositions comprising the bifunctional compounds and methods of promoting the phosphorylation of target substrates in a biological sample by administering a compound or composition described herein.
Owner:PHOTYS THERAPEUTICS INC

Use of lithocholic acid as AMPK activator in pharmaceuticals and pharmaceutical composition thereof

The present disclosure relates to the field of biopharmaceuticals, and in particular, to use of lithocholic acid (LCA) as an AMPK activator in pharmaceuticals and a pharmaceutical composition thereof. According to the present disclosure, the LCA is used as a new AMPK activator and can play a role in activating AMPK in various organs or tissues including the liver, kidney, muscle tissue, and the like of mammals, thereby achieving a significant prevention or relieving effect on various indications including high cholesterol, diabetes, and tumors, and providing a thought for developing new drugs and new therapeutic means.
Owner:XIAMEN UNIV

Use of a polypeptide in modulating lipid metabolism

PendingCN122398987AAMPKTG - Triglyceride
The application belongs to the technical field of bioactive peptides, and discloses application of a polypeptide in regulating lipid metabolism. The polypeptide is IPIQY, and the amino acid sequence is shown as SEQ ID NO. 1. The polypeptide directly acts on hepatocytes to activate AMPK. The application first discloses that the polypeptide IPIQY can directly act on hepatocytes to activate the AMPK signal pathway, and thus realizes reduction of the content of triglyceride in hepatocytes and reduction of lipid accumulation.
Owner:SICHUAN UNIV

Liver cancer prognosis marker and application thereof

The invention discloses a liver cancer prognostic marker and application thereof, relates to the technical field of molecular biomedicine, and discovers that significant correlation exists between mRNA expression quantity increase of a KDM4B gene and overall survival rate reduction of LIHC patients. GO analysis and KEGG analysis are respectively carried out on the co-expression gene of the KDM4B to obtain the correlation between the co-expression gene and signal channels such as cell cycle and AMPK, and the expression of the KDM4B is positively correlated with the immune cell infiltration level. Westernblot shows that the expression of the KDM4B in the liver cancer cell line is higher than that in normal cells. The invention provides a new marker for prognosis of liver cancer, and provides an important basis for selection of an LIHC precise treatment strategy.
Owner:PEKING UNIVERSITY THIRD HOSPITAL (THE THIRD CLINICAL MEDICAL SCHOOL OF PEKING UNIVERSITY)

Application of recombinant ITLN1 protein in preparation of products for treating renal interstitial fibrosis

The invention belongs to the technical field of biological medicine, and particularly discloses application of recombinant ITLN1 protein in preparation of a product for treating renal interstitial fibrosis. The invention discloses application of ITLN1 in treatment of renal interstitial fibrosis, ITLN1 can activate AMPK so as to increase fatty acid oxidation and relieve renal interstitial fibrosis, and a new theoretical basis and strategy are provided for clinical treatment of chronic kidney diseases.
Owner:ZUNYI NO 1 PEOPLES HOSPITAL

Medical use of AMPKγ2 protein in preventing or treating heart failure after myocardial infarction

This invention discloses the medical use of AMPKγ2 protein for preventing or treating heart failure (HF) after myocardial infarction (MI), belonging to the field of pharmaceutical biotechnology. The expression level of AMPKγ2 protein or its active fragment is correlated with HF caused by abnormal cardiac remodeling due to excessive inflammatory response after MI. MI mice with systemic AMPKγ2 knockout significantly decreased left ventricular systolic function and significantly increased macrophage infiltration; whereas MI mice with systemic AMPKγ2 overexpression showed reduced cardiac dysfunction due to MI and macrophage infiltration. Furthermore, macrophage-specific knockout of AMPKγ2 exacerbated cardiac dysfunction due to MI and macrophage infiltration; conversely, macrophage-specific overexpression of AMPKγ2 alleviated cardiac dysfunction due to MI and macrophage infiltration. This invention provides a new target for the diagnosis and treatment of HF after MI and has significant clinical significance.
Owner:GENERAL HOSPITAL OF THE NORTHERN WAR ZONE OF THE CHINESE PEOPLES LIBERATION ARMY

Methods of promoting acetyl coenzyme a-flux in cells

PCT designated stage expiredWO2024246536A1Organic active ingredientsMetabolism disorderAMPKPhosphorylation Inhibition
The present invention relates to a method of promoting and / or increasing acetyl coenzyme A (acetyl-CoA) flux into the lipid synthesis (lipogenesis) and fatty acid oxidation pathways in a cell, comprising increasing the activity of AMP-activating protein kinase (AMPK) while maintaining or increasing acetyl-CoA carboxylase (ACC1) activity in the cell. Also provided are a method of rejuvenating a cell, such as to a younger metabolic state, comprising promoting and / or increasing acetyl coenzyme A (acetyl-coA) flux into the lipid synthesis (lipogenesis) and fatty acid oxidation pathways, a pharmaceutical composition comprising a combination of an activator of AMPK and an inhibitor of ACC1 phosphorylation, and the use of said pharmaceutical composition in the treatment of age-related diseases or disorders.
Owner:BABRAHAM INST

Medicine for reversing multidrug resistance of tumor

The invention belongs to the technical field of medicine application, and particularly relates to a medicine for reversing tumor multidrug resistance. The AMPK signal channel serves as an energy sensing center, and the expression mode of the catalytic subunit PRKAA1 / 2 of the AMPK signal channel has dispute in TNBC. Previous researches show that the AMPK activity in primary breast cancer is generally reduced, and clinical data analysis shows that the AMPK expression of a patient with advanced TNBC is increased and is related to poor prognosis. The invention finds that the expression of PRKAA2 in primary TNBC tissue is reduced, but DOX treatment can induce the expression of PRKAA2, and the expression of PRKAA2 is obviously increased in drug-resistant TNBC cells and TBCSCs. Mechanism research shows that the dynamic expression regulation is derived from CTED2 dependent CBP / p300 mediated H3K27 acetylation modification. The result shows that the AMPK signal has space-time specificity in TNBC, and the function of the AMPK signal may depend on the tumor development stage and the cell subtype.
Owner:NINGBO FIRST HOSPITAL

Bifunctional kinase binding compounds and uses thereof

PCT designated stage expiredWO2025019599A3Organic active ingredientsOrganic chemistryAMPKKinase binding
Provided herein are bifunctional compounds that bind 5 '-AMP-activated protein kinase (AMPK) and / or promote targeted phosphorylation of a substrate. The induced phosphorylation of the target substrate can alter the substrate's structure and function, thus providing compounds which enable phosphorylation of target substrates, including those that may not otherwise be substrates for AMPK, and providing new modes for inducing strategic phosphorylation. Also provided are pharmaceutical compositions comprising the bifunctional compounds and methods of promoting the phosphorylation of target substrates in a biological sample by administering a compound or composition described herein.
Owner:PHOTYS THERAPEUTICS INC

A bioactive synergistic composition(s) for activating- AMPK- FOXO3a signaling pathway

PCT designated stageWO2026028220A1Metabolism disorderSexual disorderAMPKVascular ageing
The present invention relates to synergistic composition for delaying cellular senescence. Particularly, the present invention relates to the bioactive composition for activation of the AMPK-FOXO3a signaling pathway, wherein the composition comprising synergistic combination of FOXO3a promoter and AMPK activators and in specific concentration that controls cell senescence, apoptosis, and autophagy, lire present synergistic composition is useful in controlling vascular ageing disorders.
Owner:OPTICELLAR INNOVATION PTE LTD

Substituted fluorine-containing imidazole salt compound, preparation method therefor, pharmaceutical composition thereof and use thereof

Disclosed in the invention are a type of compounds having activity of activating 5'-adenosine monophosphate-activated protein kinase (AMPK), a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for reducing fatty acid synthesis, for inhibiting triglyceride and cholesterol synthesis, for preventing and / or treating obesity and type II diabetes, for preventing and / or treating tumor, for preventing and / or treating Parkinson's disease, for preventing and / or treating Alzheimer's disease or for prolonging the lifespan of mammals: <com:Math><semantics>R2<annotation encoding="application / x-tex">R_2< / annotation>< / semantics>< / com:Math> R<com:Sub>1< / com:Sub>~ <com:Math><semantics>⟨N⟩<annotation encoding="application / x-tex">\langle N \rangle< / annotation>< / semantics>< / com:Math> R<com:Sub>3< / com:Sub>
Owner:XIAMEN VIVOHEALTHS TECH CO LTD

Use of nt5c1a as a target for treatment of myocardial ischemia reperfusion injury

PendingCN122357716AProtein DRP1Atp production
This invention discloses the application of NT5C1A as a therapeutic target for myocardial ischemia-reperfusion injury, belonging to the field of biomedical technology. Through proteomics screening and in vitro and in vivo experiments, this invention is the first to discover and demonstrate that NT5C1A is upregulated in the pathological process of MIRI, and is a key upstream factor regulating the AMPK / SIRT1 / PGC-1α signaling pathway. Overexpression of NT5C1A can effectively activate this pathway, synergistically regulating multiple downstream pathological processes: promoting the expression of mitochondrial fusion proteins Mfn-2 and OPA1, inhibiting the expression of the splitting protein DRP1; significantly promoting ATP production and improving energy metabolism disorders; and regulating the balance of apoptosis-related protein Bax / Bcl-2 expression, inhibiting cardiomyocyte apoptosis, ultimately reducing myocardial damage, improving myocardial function, and reducing the infarct area. This invention provides a new target and strategy for the precise intervention of MIRI.
Owner:TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE

Heterobifunctional small molecules that deubiquitinylate and stabilize target proteins by recruiting USP7

PCT designated stage expiredWO2024233280A1Organic chemistryPharmaceutical non-active ingredientsDiseaseAMPK
Disclosed is a method and compounds for treating AMPK, cGAS, or ΔF508-CFTR mediated diseases, the method including administering one or more AMPK, cGAS, or CFTR DUBTACs to a subject who has an AMPK, cGAS, or ΔF508-CFTR -mediated disease, the AMPK, cGAS, or CFTR DUBTACs being heterobifunctional small-molecule compounds (or bivalent compounds in short) including an AMPK, cGAS, or CFTR ligand conjugated to a de-ubiquitination tag (such as a small-molecule ligand of USP7) via a linker, which would stabilize AMPK, cGAS, or CFTR. The AMPK, cGAS, or ΔF508-CFTR -mediated disease can be a disease resulting from AMPK, cGAS, or CFTR destabilization. The AMPK, cGAS, or ΔF508-CFTR-mediated disease can have reduced AMPK, cGAS, or CFTR expression relative to a wild-type tissue of the same species and tissue type. The disclosed bivalent compounds stabilize AMPK, cGAS, or CFTR by recruiting USP7.
Owner:MT SINAI SCHOOL OF MEDICINE +1